.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX29_DenileukinDiftitox.DenileukinDiftitox .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX29_DenileukinDiftitox.DenileukinDiftitox| name: | DenileukinDiftitox | |
| ATC code: | L01XX29 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 18 | mg |
| volume of distribution: | 5.4 | L |
| clearance: | 1.1 | L/h |
| other parameters in model implementation | ||
Denileukin diftitox is a recombinant fusion protein composed of interleukin-2 and diphtheria toxin fragments. It binds to the high-affinity interleukin-2 (IL-2) receptor, resulting in selective cytotoxicity against malignant cells expressing this receptor. It was previously approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), but its use has been discontinued and is not currently approved or marketed.
Pharmacokinetic parameters estimated for adults (both sexes) with cutaneous T-cell lymphoma, as peer-reviewed sources don't provide explicit compartmental PK model parameters.